Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order to retain its vibrant life sciences R&D and innovation ecosystems.
Ed, you have an extensive background in the Canadian pharmaceutical industry. How does that inform your current role as President of AstraZeneca Canada?
"Through Pascal Soriot’s global leadership, AstraZeneca has a robust and exciting global pipeline that we can leverage at the local level."
